Bioceltix has signed an agreement with PARP for funding for PLN 10.61 million

Bioceltix concluded an agreement with the Polish Agency for Enterprise Development for co-financing the project titled: “Development of a biological veterinary medicinal product BCX-CM-AD intended for the treatment of atopic dermatitis in dogs,” the company reported. The total cost of the project is PLN 20,025,176.82, the total amount of eligible expenses is PLN 17,687,931.54 and the total amount of funding is PLN 10,612,758.93.

Bioceltix is a biotechnology company developing medicinal products for companion animals, with particular emphasis on dogs and horses. In November 2021, the company debuted on the NewConnect market, and in September 2022 – on the main market of the WSE.


Our privacy policy